AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
2024年4月24日 - 3:00PM
AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based
international biotechnology company with two proprietary
Adeno-Associated Viral (AAV) vector platforms for large gene
delivery, today announces the publication of an abstract submitted
to The Association for Research in Vision and Ophthalmology Annual
Meeting (ARVO), to be held May 5-9 in Seattle.
“We are delighted to be presenting positive NHP
safety and efficacy data from our Stargardt program demonstrating
that AAV.ABCA4.intein vectors can be administered safely to NHPs
under an immunosuppressive protocol designed for use in man, and at
doses showing robust expression matching the pattern of endogenous
ABCA4. It is encouraging to see that our AAV.ABCA4.intein product
shows potential to treat retinal dystrophies, such as Stargardt
Disease,” said Prof. Alberto Auricchio, CSO of
AAVantgarde.
Dr. Natalia Misciattelli, CEO of
AAVantgarde explained that “This positive data in NHP is
very encouraging as it shows the potential of our Stargardt
program, and it provides hope to the underserved Stargardt patients
that currently don’t have many therapeutic options available.”
Poster Presentation details:
Presentation Number / Posterboard Number: 6097 -
B0943Abstract Title: Safety and expression following subretinal
administration of AAV.ABCA4.intein vectors in the non-human primate
retinaSession Number: 515Session Title: Gene and cell therapies and
other novel therapeutics IISession Date/Time: May 9, 2024 from 8:00
AM to 9:45 AM
About AAVantgarde
BioAAVantgarde Bio is a clinical stage, Italian
headquartered, international biotechnology company that has
developed two proprietary Adeno-Associated Viral (AAV) vector
platforms to address the gene therapy cargo capacity limitations of
AAV vectors. The AAVantgarde platforms could be used to deliver
large genes to ocular and non-ocular tissues. Co-founded by
Professor Alberto Auricchio at TIGEM (Telethon Institute of
Genetics and Medicine) in Naples, Italy, and Telethon Foundation,
AAVantgarde will initially validate the platform in the clinic in
two inherited retinal diseases with clear unmet need. For more
information, please visit: www.aavantgarde.com
Contact:Magda Blanco – Head of
Corporate Development AAVantgardePhone: +44 (0) 7522 128285Email:
m.blanco@aavantgarde.com